LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

LENZ Therapeutics, a late clinical-stage biopharmaceutical company developing aceclidine-based eye drops for presbyopia, will present at the Jefferies Global Healthcare Conference. The event, held in New York City from June 5-6, 2024, will feature LENZ’s CEO, Eef Schimmelpennink, presenting on June 6 at 2:00 p.m. ET. The presentation will be accessible via a live audio webcast on the LENZ website, with a replay available for 30 days.

Positive

• LENZ Therapeutics' participation in the Jefferies Global Healthcare Conference could increase investor interest.
• The live audio webcast of the presentation allows for broader accessibility, potentially attracting more investors.
• A replay of the webcast will be available for 30 days, providing extended visibility and engagement opportunities.

Negative

• The announcement lacks specific details on new financial or clinical data, providing actionable insights for investors.
• The company's focus on a single product, aceclidine-based eye drops, presents a concentration risk.
• No information on recent clinical trial results or approval progress, which could indicate delays or uncertainties.

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that Eef Schimmelpennink, President and Chief Executive Officer, will present and company management will participate in one-on-one meetings at the Jefferies Global Healthcare Conference being held from June 5^th- 6^th, 2024 in New York City.

Details of the event are as follows:
Date: Thursday, June 6^th, 2024
Time: 2:00 p.m. ET

The live audio webcast of the presentation can be accessed on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.

About LENZ Therapeutics
LENZ Therapeutics is a late clinical-stage biopharmaceutical company focused on the development and commercialization of the first aceclidine-based eye drop to improve vision in patients with presbyopia. LENZ’s product candidate, LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day.” LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.

Contacts:

Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com

FAQ

When will LENZ Therapeutics present at the Jefferies Global Healthcare Conference?

LENZ Therapeutics will present on June 6, 2024, at 2:00 p.m. ET.

How can I access the LENZ Therapeutics presentation at the Jefferies Global Healthcare Conference?

The presentation will be accessible via a live audio webcast on the LENZ website.

Will there be a replay available for the LENZ Therapeutics presentation?

Yes, a replay of the webcast will be available on the LENZ website for 30 days following the event.

What product is LENZ Therapeutics developing?

LENZ Therapeutics is developing aceclidine-based eye drops to improve near vision in people with presbyopia.

Who is presenting for LENZ Therapeutics at the Jefferies Global Healthcare Conference?

Eef Schimmelpennink, the President and CEO of LENZ Therapeutics, will be presenting.